{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:08:07Z","timestamp":1787238487643,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ecl.2023.07.002","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T21:42:20Z","timestamp":1692394940000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emerging Technologies and Therapeutics for Type 1 Diabetes"],"prefix":"10.1016","volume":"53","author":[{"given":"Halis Kaan","family":"Akturk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis M.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2023.07.002_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MED.0000000000000467","article-title":"Technological advances shaping diabetes care","volume":"26","author":"Akturk","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ecl.2023.07.002_bib2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/dom.14441","article-title":"Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use","volume":"23","author":"Berget","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.ecl.2023.07.002_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/dom.13933","article-title":"Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes","volume":"22","author":"Akturk","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.ecl.2023.07.002_bib4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc22-2121","article-title":"Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population","volume":"46","author":"Alonso","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2337\/dc21-2004","article-title":"Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study","volume":"45","author":"Champakanath","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/cd22-0067","article-title":"Factors Associated With Improved A1C Among Adults With Type 1 Diabetes in the United States","volume":"41","author":"Akturk","year":"2022","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ecl.2023.07.002_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/dia.2018.0142","article-title":"A\u00a0New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2337\/cd22-0102","article-title":"FreeStyle Libre 3","volume":"41","author":"Nguyen","year":"2022","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ecl.2023.07.002_bib9","article-title":"Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems","author":"Welsh","year":"2022","journal-title":"J\u00a0diabetes science and technology"},{"key":"10.1016\/j.ecl.2023.07.002_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/dia.2022.0011","article-title":"Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes","volume":"24","author":"Garg","year":"2022","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib11","article-title":"Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes","author":"Laffel","year":"2022","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.ecl.2023.07.002_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/dia.2021.0182","article-title":"Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study","volume":"24","author":"Garg","year":"2022","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib13","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2020.0654","article-title":"Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features","volume":"23","author":"Akturk","year":"2021","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/dia.2021.0203","article-title":"Real-World Performance of the MiniMed\u2122 780G System: First Report of Outcomes from 4120\u00a0Users","volume":"24","author":"Silva","year":"2022","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib15","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2023.0123","article-title":"Glycemic Outcomes During Early Use of the MiniMed\u2122 780G Advanced Hybrid Closed-Loop System with Guardian\u2122 4 Sensor","author":"Cordero","year":"2023","journal-title":"Diabetes technol ther"},{"key":"10.1016\/j.ecl.2023.07.002_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1089\/dia.2022.0491","article-title":"MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control","volume":"25","author":"Lombardo","year":"2023","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib17","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/dc22-0470","article-title":"Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study","volume":"45","author":"Matejko","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2337\/dc21-0172","article-title":"Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes","volume":"44","author":"Brown","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4155\/tde-2020-0055","article-title":"Review of the Omnipod(\u00ae) 5 Automated Glucose Control System Powered by Horizon\u2122 for the treatment of Type 1 diabetes","volume":"11","author":"Cobry","year":"2020","journal-title":"Ther Deliv"},{"key":"10.1016\/j.ecl.2023.07.002_bib20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMoa2205225","article-title":"Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes","volume":"387","author":"Russell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2023.07.002_bib21","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2337\/dc22-1478","article-title":"The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes","volume":"46","author":"Castellanos","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/dia.2022.0162","article-title":"Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes","volume":"24","author":"Akturk","year":"2022","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/dia.2021.0097","article-title":"One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology","volume":"23","author":"Breton","year":"2021","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1089\/dia.2022.0206","article-title":"Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations","volume":"24","author":"Forlenza","year":"2022","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2337\/dc22-1692","article-title":"Simplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents With Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed Loop System: A Randomized Controlled Trial Comparing Glucose Control","volume":"46","author":"Petrovski","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/dia.2019.0254","article-title":"Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis","volume":"21","author":"Kaur","year":"2019","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib27","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/19322968211035447","article-title":"Hybrid Closed-loop to Manage Gastroparesis in People With Type 1 Diabetes: a Case Series","volume":"15","author":"Daly","year":"2021","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.ecl.2023.07.002_bib28","doi-asserted-by":"crossref","first-page":"e3248","DOI":"10.1002\/dmrr.3248","article-title":"Case series of a hybrid closed-loop system used in pregnancies in clinical practice","volume":"36","author":"Polsky","year":"2020","journal-title":"Diabetes\/metabolism research and reviews"},{"key":"10.1016\/j.ecl.2023.07.002_bib29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/dia.2021.0354","article-title":"The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes","volume":"24","author":"Scully","year":"2022","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/1932296820983863","article-title":"Digital Diabetes Management: A Literature Review of Smart Insulin Pens","volume":"16","author":"Heinemann","year":"2022","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.ecl.2023.07.002_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2337\/ds18-0011","article-title":"InPen Smart Insulin Pen System: Product Review and User Experience","volume":"31","author":"Gildon","year":"2018","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.ecl.2023.07.002_bib32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/1932296816679180","article-title":"Half-Unit Insulin Pens: Disease Management in Patients With Diabetes Who Are Sensitive to Insulin","volume":"11","author":"Klonoff","year":"2017","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.ecl.2023.07.002_bib33","unstructured":"Bigfoot Unity System Features. 2023. at https:\/\/www.diabeteseducator.org\/danatech\/insulin-medicine-delivery\/find-compare-delivery-devices\/product-detail\/bigfoot-unity#:\u223c:text=Bigfoot%20Unity%20System%20includes%3A%20long,readings%20on%20demand%20without%20fingersticks."},{"key":"10.1016\/j.ecl.2023.07.002_bib34","unstructured":"Lilly Tempo pen features. 2023. Available at https:\/\/www.lillytempo.com\/how-tempo-works\/temposmart-app."},{"key":"10.1016\/j.ecl.2023.07.002_bib35","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.2337\/dc20-3063","article-title":"Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards","volume":"44","author":"Akturk","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11892-018-1037-x","article-title":"Disparities in Care Delivery and Outcomes in Young Adults With Diabetes","volume":"18","author":"Agarwal","year":"2018","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.ecl.2023.07.002_bib37","doi-asserted-by":"crossref","first-page":"e2960","DOI":"10.1210\/clinem\/dgaa236","article-title":"Racial-Ethnic Inequity in Young Adults With Type 1 Diabetes","volume":"105","author":"Agarwal","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.ecl.2023.07.002_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2337\/dc20-1663","article-title":"Racial and Ethnic Disparities in Rates of Continuous Glucose Monitor Initiation and Continued Use in Children With Type 1 Diabetes","volume":"44","author":"Lai","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2337\/dc20-0257","article-title":"A\u00a0Decade of Disparities in Diabetes Technology Use and HbA(1c) in Pediatric Type 1 Diabetes: A Transatlantic Comparison","volume":"44","author":"Addala","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.eprac.2021.05.001","article-title":"Disparities in Utilization and Outcomes With Continuous Subcutaneous Insulin Infusion in Young Adults With Type 1 Diabetes","volume":"27","author":"McKee","year":"2021","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2023.07.002_bib41","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/1932296817698499","article-title":"Inpatient Continuous Glucose Monitoring and Glycemic Outcomes","volume":"11","author":"Levitt","year":"2017","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.ecl.2023.07.002_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MED.0000000000000693","article-title":"Continuous glucose monitoring in the hospital: an update in the era of COVID-19","volume":"29","author":"Gothong","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ecl.2023.07.002_bib43","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.2337\/dc20-2856","article-title":"Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients With Diabetes","volume":"44","author":"Davis","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib44","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2337\/dc22-0716","article-title":"Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial","volume":"45","author":"Spanakis","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2023.07.002_bib45","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","article-title":"Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline","volume":"107","author":"Korytkowski","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2023.07.002_bib46","first-page":"1","article-title":"Cell Therapy for Type 1 Diabetes: From Islet Transplantation to Stem Cells","author":"Sordi","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.ecl.2023.07.002_bib47","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fbioe.2020.00786","article-title":"Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived \u03b2 Cells","volume":"8","author":"Velazco-Cruz","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.ecl.2023.07.002_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coph.2018.07.007","article-title":"Pluripotent stem cell replacement approaches to treat type 1 diabetes","volume":"43","author":"Pellegrini","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ecl.2023.07.002_bib49","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cmet.2021.03.021","article-title":"Human pluripotent stem cell-derived insulin-producing cells: A regenerative medicine perspective","volume":"33","author":"Migliorini","year":"2021","journal-title":"Cell Metabol"},{"key":"10.1016\/j.ecl.2023.07.002_bib50","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.stem.2023.04.002","article-title":"Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes","volume":"30","author":"Hogrebe","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ecl.2023.07.002_bib51","unstructured":"Vertex FDA clearance for VX-264 new drug application. 2023. Available at: https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-fda-clearance-investigational-new-drug."},{"key":"10.1016\/j.ecl.2023.07.002_bib52","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2018.0114","article-title":"Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes","volume":"20","author":"Akturk","year":"2018","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib53","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2018.0101","article-title":"Ever-Increasing Insulin-Requiring Patients Globally","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.ecl.2023.07.002_bib54","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MED.0000000000000423","article-title":"SGLT inhibition: a possible adjunctive treatment for type 1 diabetes","volume":"25","author":"Akturk","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ecl.2023.07.002_bib55","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/s41591-022-02011-x","article-title":"Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial","volume":"28","author":"Pettus","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ecl.2023.07.002_bib56","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/dc20-2684","article-title":"The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b\/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes","volume":"44","author":"Klein","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852923000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852923000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:27Z","timestamp":1760176227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852923000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0889852923000579"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2023.07.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Technologies and Therapeutics for Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2023.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}